Pain Medicine最新文献

{"title":"RESPONSE TO COMMENT on Effect of radiofrequency ablation of genicular nerves on the isokinetic muscle strength of knee joint in patients with osteoarthritis knee: a randomized double-blind sham-controlled clinical trial.","authors":"Jeetinder Kaur Makkar, Gayathri Warrier, Monica Chhabra, Gauri Khurana, Bisman Jeet Kaur Khurana","doi":"10.1093/pm/pnaf107","DOIUrl":"https://doi.org/10.1093/pm/pnaf107","url":null,"abstract":"","PeriodicalId":19744,"journal":{"name":"Pain Medicine","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on \"Effect of radiofrequency ablation of genicular nerves on the isokinetic muscle strength of knee joint in patients with osteoarthritis knee: a randomized double-blind sham controlled clinical trial\".","authors":"Muhammed Zahid Sahin, Ridvan Isik","doi":"10.1093/pm/pnaf109","DOIUrl":"https://doi.org/10.1093/pm/pnaf109","url":null,"abstract":"","PeriodicalId":19744,"journal":{"name":"Pain Medicine","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BiFeS Block: Distinction or Redundancy?","authors":"Richard K Kim, Edward R Mariano","doi":"10.1093/pm/pnaf103","DOIUrl":"https://doi.org/10.1093/pm/pnaf103","url":null,"abstract":"","PeriodicalId":19744,"journal":{"name":"Pain Medicine","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144837282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline characteristics of participants in the Biomarkers for Evaluating Spine Treatments clinical trial: a sequential multiple assignment randomized trial for chronic low back pain†.","authors":"Bryce Rowland, Kelly S Barth, Kevin M Bell, Amber K Brooks, Andrea L Chadwick, Annika Cleven, Robert W Hurley, Sean Mackey, Kushang V Patel, Sara R Piva, Michael J Schneider, Fatima Al-Kadhi, Bernice Asante-Nketiah, Sarah Bagaason, Anna Batorsky, Jeffrey J Borckardt, Anton E Bowden, Timothy S Carey, Joel Castellanos, Lucy Chen, Brooke Chidgey, Diane Dalton, Jonathan S Dufour, Jaclyn L Eberting, Seth M Eller, Aaron J Fields, Julie M Fritz, Amber Fu, Inam Ghulamhussain, Rachel West Goolsby, Carol M Greco, Sarah Grim, Cameron A Gunn, Lindsay Hanes, Richard E Harris, Steven E Harte, Afton L Hassett, Kinsey Helton, Anna Hoffmeyer, Anastasia Ivanova, Sara Jones Berkeley, Chelsea Kaplan, Kelley M Kidwell, Gregory G Knapik, Michael R Kosorok, Gregorij Kurillo, David Li, Remy Lobo, Joseph Long, Jeffrey C Lotz, Prasath Mageswaran, Sharmila Majumdar, Jianren Mao, William S Marras, Lance M McCracken, Micah McCumber, Samuel A McLean, Miranda McMillan, Wolf Mehling, Rafael Mendoza, Ulrike H Mitchell, Vitaly Napadow, Conor O'Neill, Sydnee Pearson, Scott Peltier, Sean D Rundell, Sonja Ryser, Andrew Schrepf, Emily Schulze, John Sperger, Nam Vo, Mark S Wallace, Abigail M Wampler, Ajay D Wasan, Tristan E Weaver, Kenneth A Weber, Lauren Wilcox, David A Williams, Leslie Wilson, Jacqueline E Woo, Fadel Zeidan, Beibo Zhao, Brianna Zhou, Kevin J Anstrom, Daniel J Clauw, Gwendolyn A Sowa, Matthew C Mauck","doi":"10.1093/pm/pnaf073","DOIUrl":"10.1093/pm/pnaf073","url":null,"abstract":"<p><strong>Objective: </strong>Chronic low back pain (cLBP) is a significant public health problem in the United States. A method to identify treatments that are most likely effective for an individual patient based on their unique characteristics is needed.</p><p><strong>Methods: </strong>The Biomarkers for Evaluating Spine Treatments (BEST) Trial is a sequential, multiple assignment, randomized trial designed to estimate an optimal treatment or combination of treatments to reduce pain intensity and interference at 24 weeks in individuals with cLBP.</p><p><strong>Results: </strong>We describe the patient-reported characteristics of the BEST Trial at the Baseline visit. Data collection for extensive required phenotyping is reported. We analyzed the run-in period of the BEST Trial to evaluate predictors of run-in failure. The BEST Trial enrolled 1019 participants and randomized 805 participants (61.6% female, mean age 50.4, 12.5% Black or African American) to the first stage of treatment. We collected extensive required phenotyping on all 805 randomized BEST Trial participants, and additional optional phenotyping on 510 (63.4%) participants.</p><p><strong>Conclusions: </strong>The BEST Trial successfully enrolled a racially and geographically diverse sample of chronic low back pain patients and completed rich phenotypic assessments to inform our primary goal of identifying in whom different treatments show optimal response. We demonstrated the feasibility of collecting extensive phenotypic assessments in a multi-site clinical trial of cLBP.</p><p><strong>Clinical trial registration number: </strong>The Biomarkers for Evaluating Spine Treatments (BEST) Trial is registered on ClinicalTrials.gov. Registration number: NCT05396014 (https://clinicaltrials.gov/study/NCT05396014).</p>","PeriodicalId":19744,"journal":{"name":"Pain Medicine","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144837281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to: Fluoroscopic Contralateral Oblique View in Interlaminar Interventions: A Technical Note.","authors":"","doi":"10.1093/pm/pnaf072","DOIUrl":"10.1093/pm/pnaf072","url":null,"abstract":"","PeriodicalId":19744,"journal":{"name":"Pain Medicine","volume":" ","pages":"500"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of transforaminal epidural steroid injection on pain and disability outcomes by lumbar intervertebral disc herniation class: a prospective study.","authors":"Tuba Tanyel Saraçoğlu, Burak Erken","doi":"10.1093/pm/pnaf040","DOIUrl":"10.1093/pm/pnaf040","url":null,"abstract":"<p><strong>Importance: </strong>Transforaminal epidural steroid injection (TFESI) is a prevalent treatment modality for lumbosacral radicular pain caused by disc herniation; however, the impact of varying disc morphologies on treatment outcomes remains unclear.</p><p><strong>Objective: </strong>To evaluate the effects of TFESI on pain and disability across different lumbar disc morphologies using the Michigan State University (MSU) classification system.</p><p><strong>Design: </strong>Prospective cohort study.</p><p><strong>Setting: </strong>A single center pain management clinic.</p><p><strong>Participants and intervention: </strong>A total of 168 patients with single-level lumbar disc herniation at L4-L5 or L5-S1 treated with TFESI. Patients were divided into 7 subgroups according to the MSU classification based on MRI findings.</p><p><strong>Main outcomes and measures: </strong>The numerical rating scale (NRS) for pain and Oswestry Disability Index (ODI) for assessing disability were measured at baseline, 1-month and 3-months post-procedure.</p><p><strong>Results: </strong>TFESI significantly reduced NRS and ODI scores in all groups (P < .001). At 1-month follow-up, NRS scores of group 1B were significantly lower than those of groups 2A and 2AB (P < .001 and P = .020, respectively); at the 3-month follow-up, no differences were observed between the groups. Although ODI scores improved over time, they did not exhibit significant differences among the subgroups throughout the study period.</p><p><strong>Conclusions and relevance: </strong>TFESI effectively reduces pain and disability across varying disc morphologies. At the 1-month mark, pain relief was more pronounced in group 1B compared to 2A and 2AB groups, whereas at the 3-month mark, the results were similar between subgroups. Larger studies with longer follow-up are needed to improve patient selection criteria and optimize treatment strategies.</p>","PeriodicalId":19744,"journal":{"name":"Pain Medicine","volume":" ","pages":"440-450"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of motivational interviewing plus cognitive behavioral therapy vs shared decision making for voluntary opioid tapering in patients with chronic pain: the INSPIRE randomized pragmatic trial.","authors":"Lauren A McCormack, Mark J Edlund, Sonia M Thomas, Li-Tzy Wu, Paul R Chelminski, Kristin R Archer, Laura K Wagner, Shawn Hirsch, Jessica E Thompson, Rowena J Dolor, Timothy J Ives, Charlene M Dewey, Samantha Chang","doi":"10.1093/pm/pnaf049","DOIUrl":"10.1093/pm/pnaf049","url":null,"abstract":"<p><strong>Objective: </strong>To compare the effectiveness of motivational interviewing plus cognitive behavioral therapy vs shared decision making on change in daily dosage of prescribed opioids for individuals with chronic non-cancer pain.</p><p><strong>Design: </strong>Pragmatic randomized trial.</p><p><strong>Setting: </strong>Three health systems in the southeastern United States.</p><p><strong>Subjects: </strong>Adults (N = 525) prescribed opioid therapy for chronic non-cancer pain.</p><p><strong>Methods: </strong>Participants were randomized to Arm 1 (a motivational interviewing visit plus eight group sessions of cognitive behavioral therapy) or Arm 2 (shared decision making medical visits). The primary outcome was change in average daily opioid dosage from baseline to 12 months using prescribing data from health records. Secondary outcomes were self-reported pain interference and physical function.</p><p><strong>Results: </strong>Both arms experienced small decreases in dosage at 12 months from baseline: Arm 1 -12 milligram morphine equivalents (95% confidence interval: -19 to -4); Arm 2 - 6 milligram morphine equivalents (95% confidence interval: -14 to 2). The mean difference between arms for change in dosage, at -6 milligram morphine equivalents (95% confidence interval: -17 to 5), was neither statistically significant nor clinically meaningful. Those in Arm 1 with a mental health diagnosis had a larger reduction in dosage (-22 milligram morphine equivalents, 95% confidence interval: -33 to -11) than those in Arm 1 without a mental health diagnosis and those in Arm 2 with a mental health diagnosis (interaction P = .10). No change from baseline occurred in pain interference or physical function for either arm.</p><p><strong>Conclusions: </strong>Additional strategies are needed to support individuals prescribed opioid therapy for chronic pain with pain management and dosage reduction. Clinicaltrials.gov registration: NCT03454555. Participant enrollment began on June 26, 2019. https://classic.clinicaltrials.gov/ct2/show/NCT.03454555. Trial sponsor: RTI International.</p>","PeriodicalId":19744,"journal":{"name":"Pain Medicine","volume":" ","pages":"477-489"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144019451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond Balance: The Cerebellum and Pain.","authors":"Michael Schmidt, Anna Woodbury","doi":"10.1093/pm/pnaf100","DOIUrl":"https://doi.org/10.1093/pm/pnaf100","url":null,"abstract":"","PeriodicalId":19744,"journal":{"name":"Pain Medicine","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144765133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Adjuvant Analgesics on Outcomes of Spinal Cord and Peripheral Nerve Stimulation: A Scoping Review.","authors":"Yilin Zhang, Sachin Sahni, Olivia Chung, Pranab Kumar, Abeer Alomari, Salim Hayek, Anuj Bhatia","doi":"10.1093/pm/pnaf105","DOIUrl":"https://doi.org/10.1093/pm/pnaf105","url":null,"abstract":"<p><strong>Introduction: </strong>Spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS) are used to treat refractory pain, but even well-selected patients can fail to have analgesic benefit following implantation. The analgesia afforded by SCS/PNS may be enhanced or attenuated by the ongoing use of analgesic medications that are often consumed by patients who receive SCS and PNS implants. We undertook a scoping review to scan and summarize the evidence for impact of adjuvant pharmacotherapy on SCS and PNS therapy in animal and human settings.</p><p><strong>Materials and methods: </strong>A comprehensive medical literature review was performed on major medical databases including MEDLINE, EMBASE, CINAHL, CENTRAL and Google Scholar from inception until July 31, 2024, for both human and animal studies. Data on the effect of pharmacotherapy on SCS analgesic efficacy and adverse effects was extracted and summarized using the Arksey and O'Malley population, concept, context (PCC) model for scoping reviews.</p><p><strong>Results: </strong>Twenty-seven studies, nine on animals and 18 on humans were identified. In human studies, SCS non-responders with neuropathic pain had analgesia restored by addition of intrathecal baclofen and clonidine. Patients who eliminated opioid use, or who were opioid naive, had superior clinical outcomes with SCS compared to those continuing opioids. Cannabinoids were associated with enhanced SCS analgesia. Patients on benzodiazepines had higher likelihood of SCS explantation. Animal studies showed intrathecal ketamine restored SCS analgesic benefits, while baclofen, clonidine, cannabinoid receptor agonists, tricyclic antidepressants, serotonin and norepinephrine reuptake inhibitors, augmented SCS responses while benzodiazepines were found to inhibit analgesic effects of PNS (see Figure 1-Graphical abstract).</p><p><strong>Conclusions: </strong>This review indicates that adjunctive analgesic therapy may play a significant role in either enhancing or attenuating analgesic benefits from SCS and PNS. By optimizing the use of analgesic medications, it may be possible to restore or enhance pain relief from both SCS and PNS.</p>","PeriodicalId":19744,"journal":{"name":"Pain Medicine","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144765134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting adherence and clinical response of cognitive behavioral therapy among individuals with chronic low back pain plus depressive symptoms: a secondary analysis of a randomized controlled trial.","authors":"Juan P Sanabria-Mazo, Estíbaliz Royuela-Colomer, Jaime Navarrete, Carla Rodríguez-Freire, Brenda Robles, Lance M McCracken, Albert Feliu-Soler, Juan V Luciano","doi":"10.1093/pm/pnaf020","DOIUrl":"10.1093/pm/pnaf020","url":null,"abstract":"<p><strong>Background: </strong>Identifying predictors for adherence and clinical response to psychological therapies is essential for improving individual treatment outcomes.</p><p><strong>Objective: </strong>To explore predictors of adherence and clinical response among individuals with co-occurring chronic low back pain (CLBP) and depression receiving cognitive behavioral therapy (CBT).</p><p><strong>Methods: </strong>This study employs a secondary analysis of data from a randomized controlled trial (NCT04140838), including 156 individuals with CLBP plus depressive symptoms who received CBT. Multiple linear regression analyses were conducted to assess the predictive power of sociodemographic, health status, pain-related, and therapy-related variables on adherence and clinical response. Adherence was measured by therapy progress (number of completed sessions) and therapy completion (attendance at least 6 out of 8 sessions). Clinical response was assessed by a clinically relevant reduction in posttreatment pain interference.</p><p><strong>Results: </strong>Older age, higher therapy credibility, and higher education level predicted greater therapy progress, while higher therapy credibility and lower baseline stress levels predicted greater therapy completion. In addition, higher opioid use, baseline pain interference, and baseline depression levels predicted lower clinical response; in contrast, higher behavioral activation levels, older age, and unemployment predicted higher clinical response.</p><p><strong>Conclusion: </strong>Therapy credibility, age, and education level are key predictors of adherence, and baseline levels of pain interference, depression, and behavioral activation are key predictors of clinical response. These findings may inform opportunities to develop more effective personalized therapeutic plans for individuals with CLBP and depression.</p>","PeriodicalId":19744,"journal":{"name":"Pain Medicine","volume":" ","pages":"459-467"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}